Kueiyu Joshua Lin

May 8, 2024 | onlinelibrary.wiley.com | Shirley Wang |Kueiyu Joshua Lin |Sebastian Schneeweiss

CONFLICT OF INTEREST STATEMENT Dr. Schneeweiss is the principal investigator of the FDA Sentinel Innovation Center funded by the FDA, co-principal investigator of an investigator-initiated grant to the Brigham and Women's Hospital from Boehringer Ingelheim and UCB Pharma unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity.

Jun 24, 2023 | agsjournals.onlinelibrary.wiley.com | Stephanie Sison |Kueiyu Joshua Lin |Mehdi Najafzadeh |Darae Ko

CLINICAL INVESTIGATION Earlier versions of this work were presented as posters during the 2021 American Geriatric Society Meeting and 2022 Gerontological Society of America Meeting. Abstract Background Among older adults, non-cardiovascular multimorbidity often coexists with cardiovascular disease (CVD) but their clinical significance is uncertain.

Mar 20, 2023 | jamanetwork.com | Kueiyu Joshua Lin |Daniel E. Singer |Darae Ko |Robert J Glynn

Key PointsQuestion  What is the association of frailty level with oral anticoagulant outcomes in terms of home time, clinical events, and total health care costs in patients with atrial fibrillation (AF)? Findings  In this cohort study of 136 551 Medicare beneficiaries with AF, apixaban was associated with increased home time and fewer clinical events than rivaroxaban and warfarin, with greater differences among those with frailty.